Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Trillium Therapeutics Inc. | tm219504d1_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - Trillium Therapeutics Inc. | tm219504d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Trillium Therapeutics Inc. | tm219504d1_ex31-1.htm |
| EX-21.1 - EXHIBIT 21.1 - Trillium Therapeutics Inc. | tm219504d1_ex21-1.htm |
| EX-10.19 - EXHIBIT 10.19 - Trillium Therapeutics Inc. | tm219504d1_ex10-19.htm |
| EX-10.18 - EXHIBIT 10.18 - Trillium Therapeutics Inc. | tm219504d1_ex10-18.htm |
| EX-10.17 - EXHIBIT 10.17 - Trillium Therapeutics Inc. | tm219504d1_ex10-17.htm |
| EX-10.16 - EXHIBIT 10.16 - Trillium Therapeutics Inc. | tm219504d1_ex10-16.htm |
| EX-10.15 - EXHIBIT 10.15 - Trillium Therapeutics Inc. | tm219504d1_ex10-15.htm |
| EX-4.3 - EXHIBIT 4.3 - Trillium Therapeutics Inc. | tm219504d1_ex4-3.htm |
| EX-3.3 - EXHIBIT 3.3 - Trillium Therapeutics Inc. | tm219504d1_ex3-3.htm |
| EX-3.2 - EXHIBIT 3.2 - Trillium Therapeutics Inc. | tm219504d1_ex3-2.htm |
| 10-K - FORM 10-K - Trillium Therapeutics Inc. | tm219504d1_10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-251262), pertaining to the 2018 Amended and Restated Stock Option Plan and the 2020 Omnibus Equity Incentive Plan of Trillium Therapeutics Inc., of our report dated March 18, 2021, with respect to the consolidated financial statements of Trillium Therapeutics Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
| /s/ Ernst & Young LLP | ||
| Toronto, Canada, | Chartered Professional Accountants | |
| March 18, 2021 | Licensed Public Accountants |